ArticleJournal of asthma and allergy2026
Impact of Fluticasone Furoate/Vilanterol on Small Airway Function in Asthma: A Real- World Study Using Impulse Oscillometry Stratified by Eosinophilic Inflammation.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small airway dysfunction (SAD) is a key component of asthma pathophysiology that may persist despite adequate treatment. Impulse oscillometry (IOS) provides sensitive detection of peripheral airway abnormalities beyond conventional spirometry. Fluticasone furoate/vilanterol (FF/VI) is a widely used once-daily inhaled corticosteroid/long-acting β Methods: Patients with asthma who received FF/VI for 12 months were retrospectively reviewed. Pulmonary function tests, including forced expiratory volume in one second (FEV Results: After one year of treatment, mean FEV Conclusion: FF/VI 92/22 μg delivered via the Ellipta device significantly improved spirometric indices and central airway resistance. Improvements in small-airway mechanics were observed in patients with lower eosinophilic inflammation, suggesting that eosinophilic inflammation may be associated with attenuated small airway response. Further prospective studies are warranted to better define the role of inflammatory status in small airway dysfunction and to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.